Go to deals
Healthcare

Olyos Group has acquired a controlling stake in NewScience

Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.

Olyos, headquartered in France, has been controlled since 2023 by European private equity firm Motion Equity Partners. With over 75 years of history, Olyos is an international nutrition and health platform, generating US$150 million (€130 million) in annual revenues. Olyos’ strategy is based on a combination of organic and inorganic growth across its brands, supported by a scientific and pharmaceutical-driven approach. To date, the group has completed seven strategic acquisitions to expand its geographic footprint.

Founded over 15 years ago by Juan Pablo Salas, NewScience is a well-established company in the nutritional supplements market, with a strong presence across categories such as omega-3, probiotics, specialized magnesium, collagen, vitamins and minerals. The company is the market leader in omega-3 supplements. NewScience operates a fully integrated, asset-light business model, outsourcing manufacturing, packaging and quality control, while focusing on R&D, top-tier suppliers and a strong commercial strategy. This approach has enabled the company to establish a presence in more than 1,700 points of sale, as well as digital channels. NewScience has nationwide coverage in Chile, operations in Ecuador and international expansion plans currently underway.

Oaklins’ team in Chile acted as the exclusive buy-side financial advisor to Olyos in the acquisition of a controlling stake in NewScience S.A. It provided strategic and financial advice throughout the transaction, including valuation analysis, transaction structuring and negotiations with the sellers. Oaklins’ French team supported the early stages of the transaction, including the introduction that led to the mandate and the initial connection with Olyos.

Parties

Talk to the deal team

Agustin Achondo

Director
Santiago, Chile
Oaklins LarrainVial

Antoine Lemaire

Partner
Paris, France
Oaklins France

Nicole Leigh

Senior Associate
Santiago, Chile
Oaklins LarrainVial

Inés Pfingsthorn

Analyst
Santiago, Chile
Oaklins LarrainVial

Related deals

UKAT Group has acquired Bayberry Limited
Private Equity | Healthcare

UKAT Group has acquired Bayberry Limited

UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.

Learn more
Medicija has acquired Saulės Šeimos Medicinos Centras
Healthcare

Medicija has acquired Saulės Šeimos Medicinos Centras

Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.

Learn more
Quimpharma has completed the divestiture of a product portfolio to Megalabs
Healthcare

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Quimpharma has completed the divestiture of a product portfolio to Megalabs México.

Learn more